Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 2:120:e240229.
doi: 10.1590/0074-02760240229. eCollection 2025.

Parasitological cure and clinical benefits of benznidazole treatment in patients from the Jequitinhonha Valley, MG, Brazil, with recent chronic infection by Trypanosoma cruzi II

Marta de Lana  1   2 , Lourena Tomazelli Suave  1 , Júlio César Santoro de Oliveira Assis  1 , Girley Francisco Machado de Assis  3 , Matheus Marques Milagre  2 , Glaucia Diniz Alessio  4 , Renato Afonso Salgado  5 , Olindo Assis Martins-Filho  4 , Pedro Albajar-Viñas  6 , Rosália Morais Torres  7
Affiliations

Parasitological cure and clinical benefits of benznidazole treatment in patients from the Jequitinhonha Valley, MG, Brazil, with recent chronic infection by Trypanosoma cruzi II

Marta de Lana et al. Mem Inst Oswaldo Cruz. .

Abstract

Background: The treatment of the early chronic phase of Chagas disease (CD) may result in high rates of parasitological cure, which may be associated with clinical benefits.

Objectives: To evaluate children with CD from the Jequitinhonha Valley, MG, Brazil, treated with benznidazole (BZ), employing classic and alternative methodologies.

Methods: Before and after treatment, nine individuals were examined by haemoculture, polymerase chain reaction (PCR), conventional enzyme-linked immunosorbent assay (ELISA), electrocardiogram, echocardiogram, and thoracic and gastrointestinal X-ray. Eight individuals were in the indeterminate clinical form of CD, and one was in the mild cardiac form. After treatment, all individuals were re-evaluated periodically for 4-26 years using the same methodologies cited and anti-live trypomastigotes antibodies by flow-cytometry-FC-ALTA and quantitative PCR (qPCR).

Findings: The cure rate by the classic cure criteria was 33.33%. By the alternative cure criteria using FC-ALTA and qPCR, the rates of cure were 50% and 78%, respectively. Post-treatment clinical evaluations revealed stability in 5/9 and discrete clinical evolution in 4/9 individuals.

Main conclusions: It was demonstrated the effectiveness of BZ treatment in recent chronic infections of CD with low or higher rates of parasitological cure according to the cure criterion used after long-term follow-up. The clinical status of the individuals remained stable or evolved slowly, suggesting clinical benefits from BZ treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest

Figures

Fig. 1:
Fig. 1:. Chagas disease patients - Prospective laboratory and clinical follow-up after benznidazole (BZ) treatment.
Fig. 2:
Fig. 2:. long-term follow-up of Chagas disease patients treated with benznidazole (BZ) in the recent chronic infection by parasitological (haemoculture), conventional serology enzyme-linked immunosorbent assay (ELISA), non-conventional serology (flow cytometry anti-live trypomastigote antibodies - FC-ALTA), and molecular polymerase chain reaction (PCR) and quantitative PCR (qPCR) methods.
Fig. 3:
Fig. 3:. long-term follow-up of Chagas disease patients treated with benznidazole (BZ) in the recent chronic infection by conventional enzyme-linked immunosorbent assay (ELISA) and non-conventional (flow cytometry anti-live trypomastigote antibodies - FC-ALTA) serologies and molecular [quantitative polymerase chain reaction (qPCR)] methods.
See this image and copyright information in PMC

References

    1. Guhl F. Teilleria J, Tibayrenc M. American trypanosomiasis Chagas disease one hundred years of research. 2. Amsterdam: Elsevier Science; 2017. Geographical distribution of Chagas disease; pp. 89–106.
    1. WHO World Chagas Disease Day 2023. 2023. https://www.who.int/campaigns/world-chagas-disease-day/2023
    1. Bern C, Messenger LA, Whitman JD, Maguire JH. Chagas disease in the United States a public health approach. Clin Microbiol Rev. 2020;33(1):e00023–e00019. doi: 10.1128/CMR.00023-19. - DOI - PMC - PubMed
    1. López-García A, Gilabert JA. Oral transmission of Chagas disease from a one health approach a systematic review. Trop Med Int Health. 2023;28(9):689–698. doi: 10.1111/tmi.13915. - DOI - PubMed
    1. Spinello A, Galimberti L, Bianco R, Grande R, Galli M, Corbellino M. Chagas disease in Europe a review for the internist in the globalized world. Eur J Inter Med. 2017;43:06–15. doi: 10.1016/j.ejim.2017.05.001. - DOI - PubMed

MeSH terms